Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2024-04-26 00:00:00 ET · period of report 2024-04-24 · accession 0002001011-24-000048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-26 | 2024-04-24 | LGND | KOZARICH JOHN W | Dir | M - OptEx | $39.35 | +2,893 | 42.5K | +7% | +$113.8K |
| D | 2024-04-26 | 2024-04-24 | LGND | KOZARICH JOHN W | Dir | M - OptEx | $0.00 | -2,893 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-04-24 | M | A | 2,893 | $39.35 | 42,523 | D | — | — | |
| 2 | Derivative | Non-Qualified Stock Option (right to buy) | 2024-04-24 | M | D | 2,893 | $0.00 | 0 | D | $39.35 · — to 2024-06-04 | 2,893 Common Stock | (F1) This Option was previously reported as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer. |